Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH: Tinostamustine + Pembrolizumab + Rituximab in DLBCL
NCT04279938Phase 1Withdrawn
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tinostamustine in diffuse large B-cell lymphoma (DLBCL), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Number of participants with treatment-related adverse events at 2.3 years. Planned start Sep 2018; status: withdrawn.
02
Drugs
tinostamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04279938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279938.